Printer Friendly

Costa Rica : Intrexon, Ziopharm strike deal with University of Texas' MD Anderson Cancer Center.

Cutting in on the fervor over a new class of immunotherapies for cancer, Partners Intrexon and Ziopharm have signed an agreement with the University of Texas' MD Anderson Cancer Center.

The deal will see the partners giving $100 million to MD Anderson for a CAR-T technology, made through a process in which researchers remove T cells from a patient's blood and provide them with targeting mechanisms called chimeric antigen receptors (CARs), which seek out and bind to proteins that cancer cells express.

The ensuing cells are re-entered into the patient, at which point they find out malignancies and attack them as they would any normal infection.

MD Anderson's approach, called Sleeping Beauty, makes use of a nonviral gene transfer system to get those modified T cells to their targets, in contrast to major CAR-T therapies from Novartis ($NVS), Juno Therapeutics ($JUNO), Kite Pharma ($KITE) and others.

Researchers say, that offers some safety benefits, as MD Anderson's approach has so far avoided some of the harmful immune responses that have afflicted competing CAR-T programs.

2014 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Jan 16, 2015
Previous Article:China : AVIC Aircraft Company selects AMETEK fuel gauging system for MA700 turboprop.
Next Article:Germany : Evonik launches DEGALAN VP P 34, a new heat-sealing binder, on the market.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters